[Federal Register Volume 83, Number 189 (Friday, September 28, 2018)]
[Notices]
[Page 49074]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21152]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License for U.S. Government-Owned 
Invention

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with applicable laws and regulations, 
announcement is made of the intent to grant an exclusive within a field 
of use, royalty-bearing, revocable biological materials license.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
MD 21702-5012.

FOR FURTHER INFORMATION CONTACT:  Mr. Barry Datlof, Office of Research 
& Technology Applications, (301) 619-0033, telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i), announcement is made of the intent to grant an 
exclusive within a field of use, royalty-bearing, revocable biological 
materials license to 45AZ Dengue-1 strain to PrimeVax Immuno-Oncology, 
Inc., having its principal place of business at 2229 W Mills Drive, 
Orange, California 92868.
    Anyone wishing to object to grant of this license can file written 
objections along with supporting evidence, if any, within 15 days from 
the date of this publication. Written objections are to be filed with 
the Command Judge Advocate (see ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2018-21152 Filed 9-27-18; 8:45 am]
 BILLING CODE 5001-03-P